T he renin-angiotensin system is a complex hormonal system composed of multiple enzymes, peptides, and receptors controlling sodium (Na + ) excretion and blood pressure (BP).
T he renin-angiotensin system is a complex hormonal system composed of multiple enzymes, peptides, and receptors controlling sodium (Na + ) excretion and blood pressure (BP). 1, 2 Angiotensin II (Ang II), its major effector peptide, acts at 2 major angiotensin receptors, the type-1 (AT 1 R) and type-2 (AT 2 R) receptors. The vast majority of Ang II biological actions are mediated by AT 1 Rs, including vasoconstriction, antinatriuresis, cellular dedifferentiation and growth, aldosterone secretion, and sympathetic nervous system activation, each of which can increase BP. In contrast, AT 2 Rs generally induce the opposite effects, including vasodilation, natriuresis, cellular differentiation, and growth inhibition. 1 Because AT 1 Rs are expressed at a higher level than AT 2 Rs in most adult tissues, including vasculature and the kidney, AT 1 R actions usually predominate in vivo, especially under baseline unstimulated conditions. However, on renin-angiotensin system stimulation or during AT 1 R blockade, when unblocked AT 2 Rs are exposed to high levels of angiotensin, AT 2 R-mediated vasodilation and natriuresis can readily be demonstrated. [3] [4] [5] 
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According to the Guyton hypothesis, 6, 7 the kidneys play a critical role in the control of BP by regulating Na + excretion. Under normal physiological conditions, a primary increase in renal Na + retention expands extracellular fluid volume and increases BP. However, the increase in BP in turn is offset by pressure-induced natriuresis, returning BP to or toward its original baseline level. The development of hypertension requires an abnormality in pressure natriuresis, wherein the increase in BP is accompanied by a natriuretic response that is insufficient to lower BP to normal.
The renal proximal tubule (RPT) is a critical nephron segment in the development of hypertension induced by Ang II.
Gurley et al 10 have demonstrated in cross-transplantation studies in renal tubule-selective AT 1 R knockout mice that AT 1 Rs must be present in the RPT to sustain a hypertensive response to continuous systemic Ang II infusion. Li and Zhuo 11 recently have confirmed the critical importance of RPT AT 1 Rs to control BP through their actions to increase Na + reabsorption by demonstrating in AT 1 R-null mice that transfer of AT 1 Rs into RPT cells (RPTC) enables a hypertensive response to Ang II.
AT 2 Rs are expressed in the adult kidney RPT. 12, 13 Recently, we demonstrated that acute systemic administration of the highly selective nonpeptide AT 2 R agonist compound 21 (C-21) induces natriuresis by activating and recruiting AT 2 Rs to the apical plasma membranes of RPTCs in vivo.
14-16 C-21-induced AT 2 R activation evoked a bradykinin-NO-cGMP signaling cascade that stimulated downstream signaling mediators Src kinase and extracellular signal-related kinase (ERK), internalizing/inactivating major RPT Na + transporters Na + -H + exchanger-3 (NHE-3) and Na + /K + ATPase (NKA) resulting in natriuresis. 16 Preliminary data indicated that AT 2 R activation might prevent Na + retention and lower BP by improving the pressure-natriuresis relationship in Ang II-dependent hypertension. 16 The present study was designed to explore in depth the therapeutic potential of AT 2 R activation in the Ang II infusion model of experimental hypertension in the rat. We hypothesized that AT 2 R activation would increase Na + excretion and prevent or reverse hypertension chronically in this model via an action in the RPT. Here, we show that both systemic and intrarenal AT 2 R activation with C-21 reduces BP and augments cumulative Na + excretion chronically in a model of Ang II-dependent hypertension. Our results suggest that long-term AT 2 R activation is a potential new approach in the treatment of Na + /fluid-retaining states and hypertension in humans.
Methods
Please see the Online Data Supplement for detailed methods (telemetric BP probe and systemic and intrarenal mini-pump implantation for chronic systemic and intrarenal C-21 infusion studies, respectively; standard protocol for acute in vivo studies, renal cortical interstitial infusion and BP measurements for acute in vivo studies; total renal cortical homogenate preparation and Western blot analysis; RPTC apical membrane isolation and Western blot analysis; in vivo kidney perfusion and fixation procedure; confocal immunofluorescence microscopy; and specific experimental protocols).
Animal Preparation
All experimental protocols were approved by the Animal Care and Use Committee at the University of Virginia and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The experiments were conducted on 12-week-old female Sprague-Dawley rats (Harlan; n=182). Female animals were used to maximize the renal expression of AT 2 Rs. 17 All animals were housed in a vivarium under controlled conditions (temperature, 21±1 °C; humidity, 60±10%; light, 8:00-20:00) and fed a normal Na + diet (0.3% Na + ; Harlan).
Urine Na + and Plasma Potassium Measurements
Urinary Na + and plasma potassium concentrations were measured using a flame photometer (Instrumentation Laboratory-943) and reported as μmol/min and mmol/L, respectively. Cumulative Na + balance was measured as the amount of Na + consumed minus urinary sodium excretion (U Na V) and reported as mEq.
Pharmacological Agents
C-21 (60 ng/kg/min for chronic intrarenal studies, 300 ng/kg/min for chronic systemic studies, and 100, 200, and 300 ng/kg/min for acute systemic studies; Vicore Pharma), a highly selective, nonpeptide AT 2 R agonist (K i =0.4 mol/L) was used to activate intrarenal and systemic AT 2 Rs. C-21 demonstrates 25 000-fold selectivity at AT 2 Rs compared with AT 1 Rs. 15 C-21 was administered systemically at doses that are selective for AT 2 Rs in the rat. 15 The intrarenal dose of C-21 was chosen as 20% of the systemic dose based on renal blood flow. Ang II (200 ng/kg/min; Bachem) was used to induce Ang II-dependent hypertension. PD-123319 (PD; 10 μg/kg/min; ParkeDavis), a specific AT 2 R antagonist (IC 50 =2×10 −8 mol/L and >1×10 −4 mol/L for AT 2 R and AT 1 Rs, respectively), was used to block intrarenal AT 2 Rs. Amiloride (0.8 μg/kg/min; Tocris) was used to inhibit intrarenal epithelial sodium channel activity. Chlorothiazide (0.1 μg/ kg/min; Sigma) was used to inhibit intrarenal sodium-chloride channel activity. Amiloride and chlorothiazide doses were administered on the basis of dose-ranging studies with target incremental natriuretic responses of 1 to 2 µmol/min.
Statistical Analysis
Data are presented as mean±1 SE. Statistical significance was determined using 1-way ANOVA followed by multiple comparisons testing with the Student-Newman-Keuls test with 95% confidence interval. The level of significance was set at P<0.05. Figure 1A ; Online Figure IA ), although PD did cause a nonsignificant increase in SBP. Chronic intrarenal administration of the nonpeptide AT 2 R agonist C-21 abolished the systolic pressor response to systemic Ang II on day 1 (F=7.03; P<0.01) and throughout the 7-day infusion period (F=4.54; P<0.001) with a parallel reduction in diastolic BP (Online Figure IA) . Next, we determined whether systemic C-21 infusion would induce a similar depressor action as intrarenal infusion. Systemic C-21 again abolished the increase in SBP in response to Ang II on infusion day 1 (F=18.54; P<0.001) and throughout the 7-day infusion period (F=7.33; P<0.001) with a parallel reduction of diastolic BP (Online Figure  IA) . There was no significant difference in hypotensive responses to intrarenal versus systemic C-21 administration. Activity levels (Online Figure IB) were not significantly changed by Ang II, C-21, or PD. Similarly, cardiac output and total peripheral vascular resistance measurements (Online Figure II) were not significantly influenced by any of the experimental agents.
Results

Effects of Chronic Intrarenal and
Effects of Chronic Intrarenal and Systemic C-21 infusion on 24-Hour U Na V and Cumulative Na +
Balance in Ang II-Dependent Hypertension
As shown in Figure 1B , systemic Ang II administration reduced 24-hour U Na V from 0.92±0.04 to 0.33±0.06 µmol/min (F=61.89; P<0.0001) on day 1. Subsequently, there was no significant difference in U Na V responses to Ang II or vehicle control. Although the antinatriuretic effects of systemic Ang II in the presence or absence of PD were similar during the first 24 hours, intrarenal PD administration enhanced the antinatriuretic response to systemic Ang II (F=6.76; P<0.001) during the entire 6-day collection period. Intrarenal administration of C-21 abolished the antinatriuretic response to systemic Ang II on day 1 (F=5.05; P<0.05) and reduced Ang II-mediated Na + retention during the entire 6-day period (F=4.71; P<0.01).
Cumulative Na + balance is depicted in Online Figure  III . In response to systemic Ang II infusion, cumulative Na + balance increased from 0 to 0.32±0.36 mEq on day 1 after which Na + balance returned to control levels for the remaining 5 days of study. Concurrent administration of intrarenal PD induced a similar degree of positive Na + balance on day 1 but resulted in a more positive Na + balance for the entire study period (F=2. We then determined whether the natriuretic actions of C-21, which occur largely in the RPT, would be additive to those of diuretics acting in the distal tubule and cortical collecting duct. In acute experiments in anesthetized rats, systemic C-21 administration induced a dose-dependent natriuretic response (F=19.3; P<0.001; Figure 2A ). Epithelial sodium channel inhibitor amiloride administered intrarenally induced a similar dose-dependent natriuretic response (F=7.6; P<0.001). Combination of systemic C-21 and intrarenal amiloride induced a greater natriuretic response compared with either systemic C-21 (F=5.6; P<0.01) or intrarenal amiloride (F=7.1; P<0.001) alone. The U Na V response to the combination of systemic C-21 and intrarenal amiloride was additive. Similarly, intrarenal chlorothiazide induced a dose-dependent natriuretic response (F=6.1; P<0.001). The combination of systemic C-21 and intrarenal chlorothiazide also induced a greater increase in U Na V than either C-21 (F=7.9; P<0.001) or chlorothiazide (F=4.0; P≤0.01) alone.
Again, the natriuretic response to C-21 and chlorothiazide was additive. As shown in Figure 2B , there was no significant change in mean arterial pressure from control with any of these agents in these acute experiments. To determine whether AT 2 R activation with C-21 in the presence of Ang II still induces receptor translocation to the apical plasma membranes of RPTCs, we used confocal immunofluorescence microscopy and Western blot analysis. Figure 3A depicts the subcellular distribution of AT 2 Rs as determined by confocal immunofluorescence microscopy in a representative set of rat RPTCs in response to systemic vehicle (control), systemic Ang II infusion, systemic Ang II+systemic C-21, and systemic Ang II+intrarenal C-21. The RPTC apical plasma membrane marker phalloidin (red), subapical membrane marker adaptor protein-2 (AP2; blue), and the AT 2 R (green) are depicted sequentially left-toright for all 4 conditions. As shown in the merged, enlarged merged, and enlarged AT 2 R photomicrographs ( Figure 3A with quantifications shown in Figure 3B ), administration of Ang II alone reduced AT 2 R intensity in the apical plasma membrane from control levels (P<0.001). Systemic C-21 markedly increased AT 2 R fluorescence intensity in the apical plasma membrane as indicated by the increased yellow fluorescence in the merged and enlarged merged panels and as green fluorescence in the enlarged AT 2 R panel (P<0.001). Similar to systemic C-21 infusion, intrarenal administration As shown in Figure 4A , there was no significant difference among control, systemic Ang II, or systemic Ang II+systemic C-21 in total cortical homogenate AT 2 R protein by Western blot analysis, although there was a nonsignificant trend to reduced levels in Ang II-infused animals. To complement the immunofluorescence studies on AT 2 R recruitment, we isolated RPTC apical plasma membranes using the lectin pull-down method. Western blot analysis clearly demonstrated AT 2 R recruitment to the RPTC apical plasma membranes in response to systemic C-21 (P<0.01; Figure 4B ). There was a nonsignificant decrease in RPTC apical plasma membrane AT 2 Rs in response to Ang II alone. Similarly, intrarenal C-21 increased apical membrane expression of AT 2 R protein without changing total AT 2 R levels as determined in cortical homogenates (Figure 4C and 4D; P<0.01). Ang II reduced total cortical AT 2 R protein levels (P<0.05) in these experiments.
Effects of Systemic or
Effects of Systemic or Intrarenal C-21 Infusion on 24-Hour Total Cortical Homogenate and RPTC Apical Plasma Membrane NHE-3 and Phospho-NHE-3 in Ang II-Induced Hypertension
The next experiments were aimed at determining whether chronic C-21-induced natriuresis is related to internalization and inactivation of the major RPTC apical membrane Na + transporter NHE-3. Figure 5 demonstrates the subcellular distribution for NHE-3 in response to systemic or intrarenal C-21 in Ang II-infused rats. Representative confocal micrographs are shown in Figure 5A and quantification of the relative fluorescence intensity in Figure 5B . Ang II alone did not alter total NHE-3 fluorescence intensity or distribution in RPTCs. However, systemic C-21+Ang II infusion increased the retraction of NHE-3 to the RPTC subapical membranes (P<0.01; yellow color in the subapical layer marked by AP2). Similar to systemic C-21 infusion, intrarenal C-21 increased NHE-3 translocation into the subapical membranes of RPTCs (P<0.01).
Western blot analysis of NHE-3 is shown in Figure 6 . Although Ang II or Ang II+systemic or intrarenal C-21 did not alter total cortical homogenate NHE-3 expression ( Figure 6A and 6C), systemic C-21 reduced RPTC apical plasma membrane localization of NHE-3 in isolated membranes (P<0.001; Figure 6B ) consistent with C-21-induced NHE-3 retraction shown by immunofluorescence.
Phosphorylation of NHE-3 at serines 552 and 605 after activation of cAMP-dependent protein kinase A is required for maximum inhibition of NHE-3 because the mutation of these amino acids individually reduced the inhibitory effect on NHE-3 promoted by cAMP. 18, 19 Thus, phosphorylated NHE-3 is an established indicator of NHE-3 retraction/internalization and activation. Subcellular distribution for phosphorylated NHE-3 [Ser 552] (pSer 552 -NHE-3) is shown in Figure 7 . presence of systemic C-21 (P<0.0001). A similar reduction in pSer 23 -NKA in RPTCs was observed when systemic Ang II was combined with direct intrarenal administration of C-21 (P<0.0001). 
Effects of Systemic C-21 Infusion on Total Cortical
Effects of Chronic Systemic AT 2 R Treatment on SBP After Establishment of Ang II-Induced Hypertension
As shown in Online Figure XI , systemic administration of C-21, initiated on day 3 after the establishment of Ang IIinduced hypertension, reduced both SBP (F=3.5; P<0.01) and diastolic BP (F=3.21; P<0.01) to baseline control levels by day 7.
Discussion
Our previous study in normal Sprague-Dawley rats and genetically engineered mice documented that acute systemic AT 2 R activation with C-21 induces natriuresis by translocating AT 2 Rs to the apical plasma membranes of RPTCs and internalizing/inhibiting major RPTC transporters NHE-3 and NKA. 16 This study builds on these findings by demonstrating in an Ang II infusion model of experimental hypertension that chronic AT 2 R activation with C-21 prevents initial renal Na + retention and lowers BP during a 7-day period. In addition, C-21 was an effective natriuretic and antihypertensive agent whether administered systemically or directly into the kidney in this experimental model. We also demonstrated that continuous C-21 administration, both systemically and intrarenally, induced sustained negative cumulative Na + balance accompanied by AT 2 R recruitment from intracellular sites to the apical plasma membranes of RPTCs and internalization/inactivation of major RPT Na + transporters NHE-3 and NKA. Importantly, C-21-induced natriuresis was related to inhibition of Na + transport in the RPT because it was additive to that observed with diuretics acting at either the distal tubule or the cortical collecting duct. We further demonstrated that C-21 was equally effective in lowering BP whether administered before or after Ang II-dependent hypertension had been established. Taken together, these results strongly support a role for AT 2 R agonists as natriuretic/diuretic agents that improve the pressure-natriuresis relationship and are potential candidates for the treatment of hypertension and disorders of Na + and fluid retention in humans.
In the Ang II infusion model of experimental hypertension, major Na + retention occurred within the first 24 hours of initiating the infusion, as previously reported, 16 and Na + excretion returned to approximately normal levels after 24 hours and beyond. Although the major effect of C-21 was to prevent Na + retention at 24 hours, a continuing effect of C-21 to promote negative cumulative Na + balance was observed throughout the study. Our data are highly consistent with a primary RPT action of C-21. Because we did not perform formal renal function studies, we cannot rule out a small renal hemodynamic effect as contributing to the natriuresis and reduced BP level. However, the action of C-21 was purely tubular in our previous acute study. 16 Similarly, we cannot exclude a systemic vascular effect of C-21 as contributing, at least in part, to the chronic reduction in BP in these animals. However, the fact that C-21 prevented Ang II-induced hypertension in equivalent fashion whether the C-21 was administered systemically or intrarenally argues strongly for the primacy of the kidneys in causing the reduction in BP.
Importantly, concurrent use of AT 1 R antagonist was not required to uncover the chronic natriuretic and hypotensive actions of AT 2 R agonist administration in this study. Past studies indicated that cardiovascular and renal responses to AT 2 R activation are only observed when the renin-angiotensin system is activated, as is the case in this study, or when AT 1 Rs are concurrently blocked. 1, 3, 4 Indeed, the hypotensive action of chronic C-21 was somewhat unexpected because most studies have failed to demonstrate BPlowering effects in the absence of AT 1 R blockade, albeit in spontaneously hypertensive rats or stroke-prone spontaneously hypertensive rats. 18, 20 However, further studies on the effects of the combination of AT 1 R antagonist and AT 2 R agonist administration are clearly indicated to clarify the In this study, AT 2 R activation in the presence of Ang II-induced translocation of AT 2 Rs from intracellular sites to the apical plasma membranes of RPTCs 24 hours after initiation of C-21 infusion without any alteration in total cellular AT 2 R expression, as validated by both confocal immunofluorescence studies and Western blot analysis of isolated RPTC apical membranes and total renal cortical cells. This is consistent with our previous demonstration that systemic C-21 administration acutely (at 30-90 minutes) recruits AT 2 Rs to the apical plasma membranes of RPTCs. 16 Our previous studies have shown that natriuretic responses to endogenous renal AT 2 R agonist Ang III are also accompanied by translocation of AT 2 Rs along microtubules to the apical plasma membranes of RPTCs. 19 Furthermore, dopamine D 1 receptor activation with selective receptor agonist fenoldopam induces natriuresis in an AT 2 R-dependent manner. Fenoldopam translocates AT 2 Rs to the apical plasma membranes of RPTCs via a cAMP-and protein phosphatase 2A-dependent signaling pathway. 19 Spontaneously hypertensive rats fail to develop either AT 2 R recruitment or natriuretic responses to Ang III, and both can be restored by increasing Ang III levels via blockade of aminopeptidase N. Together with the present observations, the evidence indicates that AT 2 R recruitment to the apical plasma membranes of RPTCs is likely a common mechanism initiating and sustaining long-term natriuretic responses to endogenous AT 2 R agonists dopamine and Ang III, as well as exogenous agonist C-21.
19,21,22 Because AT 2 Rs do not internalize in renal Of the Na + filtered into the nephron, ≈67% is reabsorbed isotonically in the RPT. 25, 26 The principal apical membrane Na + transporter in the RPT is NHE-3, which also participates in supporting flow-dependent glomerulotubular balance. 26, 27 NHE-3-null mice are hypovolemic and hypotensive, exhibit metabolic acidosis, reduced reabsorption of Na + , HCO 3 − , and fluid and increased mortality when subjected to low-Na + intake. 28, 29 In light of the major physiological role of NHE-3 in the RPT, relatively small changes in its activity could have significant pathophysiological consequences. Indeed, NHE-3 is among the most highly regulated transport proteins of cell membranes, modulated by multiple physiological and pathological conditions. 28 NHE-3 is expressed along the microvilli of the RPTC brush border but can also be detected in subapical, intracellular, and vesicular compartments, consistent with the regulation of its activity by membrane trafficking. 30, 31 Acute regulation of NHE-3 occurs via changes in phosphorylation, membrane trafficking, and/or membrane localization acting on the existing cellular NHE-3 pool. 32 The cytoplasmic loop of NHE-3 contains several phosphorylation sites that are targeted by different kinases. The cAMP-dependent protein kinase A phosphorylates NHE-3 in its carboxy terminus. Phosphorylation of serines 552 and 605 is required for maximum inhibition of NHE-3 by cAMP because mutation of these serines individually reduces the inhibitory effect on NHE-3 promoted by cAMP. 32, 33 Retraction/internalization of NHE-3 is a marker of reduced NHE-3 activity. 34, 35 In our previous studies, we showed that acute systemic C-21 administration (30-90 minutes) retracts NHE-3 from the tips to the bases of apical microvilli and into the subapical membranes of RPTCs as a mechanism to reduce RPTC Na + transport. 16 In the present study, we demonstrated chronic (24 hours) C-21 administration induced retraction/internalization of NHE-3 by confocal fluorescence microscopy and Western blot analysis. We further demonstrated increased total cortical homogenate pSer 552 -NHE-3 and pSer 605 -NHE-3 levels, as established indicators of NHE-3 retraction/internalization. 35, 36 In addition to NHE-3, we demonstrated a parallel internalization and inactivation of NKA, the major Na + transporter across the basolateral membranes of RPTCs. We showed that Ang II markedly reduced intracellular NKA fluorescence intensity, whereas C-21 reversed this response without change in the total cellular pool of NKA. In the rat RPT, the α-1 subunit of NKA is phosphorylated at serine 23 by the action of protein kinase C. 37 NKA phosphorylation at this site plays a major role both in the regulation of NKA enzyme activity and subcellular distribution, as demonstrated by mutation of this phosphorylation site. [38] [39] [40] In this study, we demonstrated that C-21-induced NKA dephosphorylation at serine 23, indicating retraction and inactivation of NKA.
However, we found no evidence of chronic activation of Src or ERK signaling molecules downstream of AT 2 Rs. This contrasts with C-21-induced Src and ERK activation after acute systemic administration of C-21 in our previous study that is likely explained by the early response of these pathways to AT 2 R activation and cGMP, as demonstrated previously. 16, 41 The results of this study encourage the evaluation of acute and chronic AT 2 R activation in the control of Na + excretion and BP, with and without concurrent AT 1 R blockade, in the TGR(mRen2)27 rat, a model of human primary hypertension in which the endogenous tissue renin-angiotensin system is activated, as well as a volume-expanded hypertensive model (DOCA [11-deoxycorticosterone acetate]/salt hypertension).
42,43 Future investigations will explore the potential role for AT 2 R agonists as natriuretic/diuretic agents in hypertension and disorders of Na + and fluid retention in humans. What Is Known?
• Angiotensin II (Ang II) activates 2 major receptors, type-1 (AT 1 R) and type-2 (AT 2 R).
• AT 2 R activation generally opposes the actions of Ang II via AT 1 Rs.
• Within the kidney proximal tubule, acute AT 2 R activation with nonpeptide agonist compound 21 (C-21) recruits AT 2 Rs to apical plasma membranes and increases sodium (Na + ) excretion in a bradykinin-nitric oxide-cyclic guanosine 3′,5′-monophosphate (cyclic GMP)-dependent manner in normal Sprague-Dawley rats.
What New Information Does This Article Contribute?
• Chronic AT 2 R activation (systemically or intrarenally) with C-21 increased Na + excretion and normalized blood pressure (BP) in the Ang II-infusion model of experimental hypertension.
• Chronic AT 2 R activation translocated AT 2 Rs to apical plasma membranes, internalized and inactivated sodium transporters sodium-hydrogen exchanger-3 (NHE-3) and Na + /K + ATPase (NKA) and functionally reduced sodium transport in renal proximal tubule cells.
• C-21 normalized BP whether administered before or after Ang IIdependent hypertension had been established.
Classically, Ang II induces hypertension by promoting antinatriuresis and vasoconstriction. On the contrary, acute AT 2 R activation induces natriuresis by increasing renal bradykinin, nitric oxide, and cGMP, recruiting AT 2 Rs to apical plasma membranes and internalizing and inactivating major Na + transporter molecules (NHE-3 and NKA) in the renal proximal tubules (RPT) of normal rats.
Here, we report that chronic (intrarenal or systemic) AT 2 R activation with C-21 induces sustained reduction in cumulative Na + balance and reverses Ang II-dependent hypertension by acting at the RPT. C-21, administered chronically, recruited AT 2 R to apical plasma membranes and internalized/inactivated NHE-3 and NKA in this nephron segment. C-21 normalized BP whether administered previous or subsequent to the establishment of Ang II-dependent hypertension, and the natriuresis engendered by C-21 was additive to that of diuretics acting at the distal tubule (chlorothiazide) and cortical collecting duct (amiloride), indicating a primary RPT effect.
These findings indicate that AT 2 R activation can lower BP chronically under conditions when the renin-angiotensin system is stimulated; thus, AT 2 Rs are predicted to be legitimate therapeutic targets for hypertension in humans. Currently, no effective diuretic/natriuretic agent is available that acts in the RPT. AT 2 R activation, therefore, may provide a complimentary nephron-specific site for diuresis/natriuresis in humans.
SUPPLEMENTAL MATERIAL Standard Protocol for Acute In Vivo Studies
On the day of experimentation, the rats were anesthetized with inactin (100 mg/kg body weight) via intraperitoneal (IP) injection, and a tracheostomy was performed using polyethylene tubing (PE-240) to assist respiration. Direct cannulation of the right internal jugular vein using PE-10 tubing provided intravenous access through which 2% BSA made in D 5 W or C-21 (100, 200, and 300 ng/kg/min) made in 2% BSA was infused at 50 μL/min. Direct cannulation of the right carotid artery with PE-50 tubing provided arterial access for monitoring mean arterial pressure (MAP).
After a midline laparotomy, the right kidney was excised (so that substances infused directly into the kidney would not spill over to the opposite kidney confounding the results) and the ureter of the remaining left kidney was cannulated (PE-10) to collect urine for the quantification of U Na V.
Blood Pressure (BP) Measurements for Acute In Vivo Studies
MAP was measured by the direct intra-carotid method with the use of a digital BP analyzer (Micromed, Inc). MAPs were recorded every 5 min and averaged for all periods. Experiments were initiated at the same time each day to prevent any diurnal variation in BP.
Renal Cortical Interstitial Infusion for Acute In Vivo Studies
An open-bore micro-infusion catheter (PE-10) was inserted under the renal pressure (DBP), and total activity were measured daily for 7 days at the same time each day to prevent any diurnal variation in BP measurements. In a separate group of rats, the telemetry probe was not implanted and 24h urine Na + excretion (U Na V) and cumulative Na + balance were measured daily for 6 days. In a third and fourth set of rats, kidneys were removed after 1 day of treatment for Western blot analysis or perfused for confocal microscopy respectively.
Telemetric BP Probe and Systemic Mini-Pump Implantation for Chronic Systemic
C-21 In Vivo Studies
Rats were placed under short term anesthesia for the implantation of the DSI telemetry probe as described above. The right kidney was also removed so that the rats could be compared to the chronic intrarenally infused rats. After a 1 week equilibration, 7 day SC osmotic mini-pumps for Ang II (200 ng/kg/min) and C-21 (300 ng/kg/min) infusions were implanted in the subscapular region. Mean SBP, DBP, total activity, 24h U Na V, cumulative Na + balance, and kidneys for Western blot analysis and confocal microscopy were measured and collected as described above.
Telemetric BP Probe and Systemic Mini-Pump Implantation for Chronic Systemic
C-21Treatment Following Ang II-Induced Hypertension
The procedure was as described for "Chronic Systemic C-21 In Vivo Studies" with the following modification. After the 1 week equilibration, a 7 day SC osmotic minipump infusing Ang II was placed. After SBP was measured on the third day, the rats were placed under short term anesthesia. Half of the rats received a 7 day SC osmotic mini-pump infusing D 5 W while the other half received a SC osmotic mini-pump infusing C-21. Mean SBP was then measured daily for the remaining 4 days.
Total Cortical Homogenate Preparation and Western Blot Analysis for Chronic In Vivo Studies
After 1 day of treatment, rats were anesthetized and the left kidney was removed.
Slices of kidney cortex (~100 mg) were homogenized in Mammalian Protein Extraction Reagent (MPER; Thermo Scientific) lysis buffer with Halt protease and phosphatase inhibitor cocktail (Thermo Scientific) and then centrifuged at 3100 rpm for 10 min at 4ºC
to remove cellular debris. The supernatant was removed and total protein was quantified using a bicinchoninic acid (BCA) assay (Pierce). Sodium dodecylsulfate Immunoreactivity was determined using the Odyssey Infrared Imaging System. All blots were normalized to GAPDH expression.
Renal Proximal Tubule Cell (RPTC) Apical Membrane Isolation and Western Blot Analysis for Chronic In Vivo Studies
Slices of kidney cortex (~100 mg) were homogenized in detergent free lysis buffer with
Halt protease and phosphatase inhibitor cocktail and then centrifuged at 3100 rpm for 10 min at 4ºC to remove cellular debris. Following a BCA assay to determine total protein, 1 mg of protein was resuspended in 10 mL of detergent free lysis buffer and incubated with 20 μg of biotinylated Lotus tetragonolobus agglutinin lectin (LTA; Vector Laboratories) on a 360º rocker for 2h at room temperature as previously published (1).
A 50% vol/vol slurry (20 μL) of Ultralink Neutravidin beads (Pierce) was then added and incubated on a 360º rocker for 30 min at room temperature. The beads were then pelleted and thoroughly washed using a microcentrifuge spin cup filter. The LTA affinity-attached membranes were eluted by incubating the beads in the spin cup filter with 125 μL of 70°C 2X sample buffer for 10 min and Western blot analysis was performed as previously described (1) . The membranes were incubated with AT 2 R primary antibody (1:200) and or NHE-3 (1:10) in 5% milk TBST followed by the respective HRP-conjugated secondary antibody as mentioned above. Membranes were subsequently incubated with GAPDH antibodies as described previously for normalization.
Kidney Perfusion and Fixation Procedure for Chronic In Vivo Studies
After 1 day of treatment, the rat heart left ventricular cavity was cannulated and the rat was perfused with 40 mL of 4% sucrose in PBS followed by 40 mL of 4%
paraformaldehyde ( 
MRI Measurements
Magnetic Resonance Imaging (MRI) was performed in the UVA molecular imaging core (UVAMIC) facility using the state-of-art 7T Bruker-Siemens scanner (ClinScan) for imaging rodents. Cardiac gated MRI was performed using the 7T ClinScan MRI. After attaching ECG leads to the arms of the rats, they were placed, under 1.5-2% isoflurane, in a prone position inside the radiofrequency coil. The heart rate, respiration, and core body temperature were continuously monitored using a Small Animal Monitoring and Gating system (Small Animal Instruments Inc., Stony Brook, NY). The left ventricular ejection function (LVEF) measurements were performed using ECG-triggered cine black blood pulse sequence with a slice thickness of 1.5 mm and an in-plane resolution of 100 x 100 µm 2 (7, 8) . During each session, the entire LV was imaged with 7 contiguous short-axis slices. The black blood cine images were imported to a workstation and analyzed with SEGMENT (Medviso, AB, Sweden, open source)
software. Specifically, the end-diastolic (ED) and end-systolic (ES) frames were identified and thereafter the endocardial and epicardial contours were drawn on these frames for all the slices. Using the software, the ED volume (EDV), ESV, stroke volume (EDV-ESV), ejection fraction (EF%=(EDV-ESV)/EDV) and cardiac output (CO= heart rate x stroke volume) were measured. Following the imaging studies, the rats were anesthetized and MAP measurements were taken for 30 minutes according to the methods explained previously in "BP Measurements for Acute In Vivo Studies" Vascular resistance was computed by dividing the measured MAP by the CO.
ELISA Assay Kits
A creatine colorimetric assay kit (Cayman Chemicals), an aldosterone ELISA kit (Cayman Chemicals), and renin assay kit (Sigma) were used to measure plasma levels Rats were housed continuously in metabolic cages for 6 days for urine collections. In a separate set of rats (N=6 for each condition) plasma was collected after 1 day of treatment for creatinine, aldosterone, renin activity and potassium measurements. 
